Real-World Dosing Patterns and Outcomes Among Patients With Chronic Lymphocytic Leukemia With or Without Dose Adjustment of First-Line Ibrutinib

被引：0
|
作者：
Rogers, Kerry [1 ]
Lu, Xiaoxiao [2 ]
Emond, Bruno [3 ]
Ding, Zhijie [2 ]
Lefebvre, Patrick [3 ]
Lafeuille, Marie-Helene [3 ]
Mavani, Heena [2 ]
Qureshi, Zaina [2 ]
Ghosh, Nilanjan [4 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
[2] Janssen Sci Affairs, Horsham, PA USA
[3] Anal Grp Inc, Montreal, PQ, Canada
[4] Levine Canc Inst, Charlotte, NC USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CLL; dose adjustment; real-world dosing; ibrutinib; chronic lymphocytic leukemia; outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-586
引用
收藏
页码：S330 / S330
页数：1
相关论文
共 50 条
  • [21] Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia
    Salmeron-Navas, Francisco Javier
    Barreiro-Fernandez, Ester Maria
    Fenix-Caballero, Silvia
    FARMACIA HOSPITALARIA, 2024, 48 (01) : T9 - T15
  • [22] A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib
    Mato, Anthony R.
    Tang, Boxiong
    Azmi, Soraya
    Yang, Keri
    Zhang, Xiaojuan
    Stern, Jennifer C.
    Hedrick, Eric
    Huang, Jane
    Sharman, Jeff P.
    HAEMATOLOGICA, 2022, 107 (11) : 2630 - 2640
  • [23] Real-World Treatment Switching and Sequencing to Next Line of Therapy of Zanubrutinib, Acalabrutinib, and Ibrutinib in Chronic/Small Lymphocytic Leukemia (CLL/SLL)
    Pinilla-Ibarz, Javier
    Xue, Mei
    Wu, Elizabeth
    Esselman, Kaitlyn
    Furnback, Wesley
    Challagulla, Swetha
    Yang, Keri
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S358 - S359
  • [24] Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study
    Moldovianu, Ana-Maria
    Stoia, Razvan
    Vasilica, Mariana
    Ursuleac, Iulia
    Badelita, Sorina Nicoleta
    Tomescu, Andra Alina
    Preda, Oana Diana
    Bardas, Alexandru
    Cirstea, Mihaela
    Coriu, Daniel
    MEDICINA-LITHUANIA, 2023, 59 (02):
  • [25] Real-world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK
    Hillmen, Peter
    Xie, Jing
    Yong, Alan S. M.
    Waweru, Catherine
    Sorof, Thuy Anh
    Goyal, Ravi K.
    Davis, Keith L.
    EJHAEM, 2021, 2 (02): : 219 - 227
  • [26] Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia
    Huntington, Scott F.
    de Nigris, Enrico
    Puckett, Justin
    Kamal-Bahl, Sachin
    Farooqui, Mohammed
    Ryland, Katherine
    Sarpong, Eric
    Leng, Siyang
    Yang, Xiaoqin
    Doshi, Jalpa A.
    LEUKEMIA & LYMPHOMA, 2023, 64 (14) : 2286 - 2295
  • [27] A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy
    Eichenberger, Emily M.
    Saullo, Jennifer
    Brander, Danielle
    Wang, Shih-Hsiu
    Perfect, John R.
    Messina, Julia A.
    MEDICAL MYCOLOGY CASE REPORTS, 2020, 27 : 17 - 21
  • [28] Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia
    Solman, Isabelle G.
    Blum, Lisa K.
    Hoh, Hana Y.
    Kipps, Thomas J.
    Burger, Jan A.
    Barrientos, Jacqueline C.
    O'Brien, Susan
    Mulligan, Stephen P.
    Kay, Neil E.
    Hillmen, Peter
    Byrd, John C.
    Lal, Indu D.
    Dean, James P.
    Mongan, Ann
    LEUKEMIA RESEARCH, 2020, 97
  • [29] Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia
    Burger, Jan
    Tedeschi, Alessandra
    Barr, Paul M.
    Robak, Tadeusz
    Owen, Carolyn
    Ghia, Paolo
    Bairey, Osnat
    Hillmen, Peter
    Coutre, Steven E.
    Devereux, Stephen
    Grosicki, Sebastian
    McCarthy, Helen
    Li, Jianyong
    Simpson, David
    Offner, Fritz
    Moreno, Carol
    Dai, Sandra
    Lal, Indu
    Dean, James P.
    Kipps, Thomas J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S274 - S274
  • [30] Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre
    Uminski, K.
    Brown, K.
    Bucher, O.
    Hibbert, I
    Dhaliwal, D. H.
    Johnston, J. B.
    Geirnaert, M.
    Dawe, D. E.
    Banerji, V
    CURRENT ONCOLOGY, 2019, 26 (05) : E610 - E617
12345